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Abstract
This study documents a case of coinfection (simultaneous infection of an individual with two or more
strains) of two HIV-1 subtype B strains in an individual from a Phase 3 HIV-1 vaccine efficacy trial,
conducted in North American and the Netherlands. We examined 86 full-length gp120 (env) gene
sequences from this individual collected from nine different time points over a 20-month period. We
estimated evolutionary relationships using maximum likelihood and Bayesian methods and inferred
recombination breakpoints and recombinant sequences using phylogenetic and substitutional
methods. These analyses identified two strongly supported monophyletic clades (clades A and B) of
14 and 69 sequences each and a small paraphyletic recombinant clade of three sequences. We then
studied the genetic characteristics of these lineages by comparing estimates of genetic diversity
generated by mutation and recombination and adaptive selection within a coalescent and maximum
likelihood framework. Our results suggest significant differences on the evolutionary dynamics of
these strains. We then discuss the implications of these results for vaccine development.
INTRODUCTION
Occurrence of infection with more than one strain of HIV-1 (dual infection) has important
implications for understanding HIV transmission and for AIDS vaccine development1,2 and
has led to many instances of recombinant viral strains of global epidemiologic relevance.3
Dual HIV-1 infection can be the result of either superinfection (infection with a second strain
during some period after the initial established infection) or coinfection (establishment of
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simultaneous or near simultaneous infection with two or more heterologous HIV-1 strains
within a brief period of time). The current literature defines, arbitrarily, HIV coinfection as
occurring within the first month of infection.2 Coinfection has been reported in many cases of
HIV-1-infected individuals. Some of these cases have been observations of infected individuals
with two subtypes (intersubtype)4–10 but others involved HIV-1 variants from the same
subtype (intrasub-type).11–14 Less common are the studies where recombination between
different coinfecting HIV strains has been documented.11,12 Although recombination is a
frequent phenomenon in vivo15–17 and constitutes a significant factor in assisting HIV-1
diversification and escape from host immunity and antiviral therapies, the role that
recombination and dual infection play in contributing to virus variation is not well
characterized.18 For example, the generation of new strains should be a more common
phenomenon in cases of dual infection. Additionally, an overall greater amount of genetic
diversity in a coinfected population with recombination and therefore a greater ability to defeat
an immune system, drug treatment, or vaccine treatment, potentially resulting in a faster
progression to AIDS, should be expected.
Here we report a case of coinfection between two strains of HIV-1 subtype B in a volunteer
from the world’s first Phase 3 HIV vaccine efficacy trial (VAX004). Using phylogenetic and
population genetic methods, we present congruent and well-supported evidence of
recombination between two coinfecting strains of HIV. Additionally, we genetically
characterized the evolution of these strains separately and combined using statistical
approaches of population parameter inference. Population genetics is indeed important in
understanding the evolutionary history, epidemiology, and population dynamics of pathogens,
the potential for and mode of evolution of drug and vaccine resistance, and ultimately for public
health control strategies and vaccine design.19,20 Within this framework, we examine the
population dynamics of the coinfecting HIV-1 strains by estimating and comparing their
coalescent and likelihood estimates of genetic diversity generated by mutation and
recombination, growth, and selection.
MATERIALS AND METHODS
Clinical trial and volunteer characteristics
VaxGen enrolled 5417 individuals to participate in a Phase 3 vaccine clinical trial (VAX004)
testing the efficacy of a recombinant subunit vaccine candidate (AIDSVAX B/B). The vaccine
was composed of two HIV-1 gp120 envelope protein antigens derived from the CCR5-
dependent GNE8 and CXCR4-dependent MN strains. Trial participants received up to seven
injections of vaccine or placebo over a 36-month period and were seen every 6 months for
regular HIV testing and counseling. Details of the study design and efficacy results are reported
by the rgp120 HIV Vaccine Study Group.21
From these studies, one trial participant was identified as being potentially dually infected with
at least two different HIV strains, so an additional molecular study was undertaken to analyze
the complete set of longitudinal samples from this person. The clinical progression of HIV-1
viremia and CD4 cell counts within this trial participant, a white male who received three
immunizations prior to infection, is shown in Table 1. Screening of sera samples with the
Procleix HIV-1/HCV Assay (Chiron) indicated that the first HIV-1-positive timepoint for this
volunteer was September 21, 2000 (data not shown). However, no viral load or CD4 count
information was available for that collection time. Between November 28, 2000 (T3) and
December 18, 2000 (T4) the volunteer started antiretroviral therapy. After that the viral loads
were always lower than 7 × 103 copies/ml. CD4 cell counts were higher than 550 cells/mm3
from November 20, 2000 (T2) to the end, except for July 2001 (T6), when they decreased to
380 cells/mm3.
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We present here a comprehensive analysis of phylogenetic relationships, recombination, and
population dynamics of HIV strains collected from this volunteer.
Molecular biology methods
HIV-1 gp120 viral RNA preparation and RT-PCR—Viral RNA and DNA was isolated
from 0.5–1.0 ml of frozen plasma or peripheral blood mononuclear cells (PBMCs) using the
ViroSeq Sample Preparation Kit (Applied Biosystems, Foster City, CA) and following the
manufacturer’s instructions. Full-length gp120 sequences were amplified from samples using
reverse-transcription polymerase chain reaction (RT-PCR). Random hexa-mers were utilized
for the RT reaction followed by nested PCR reactions with the first round primers ED3/ED14
(ED3 5’-TTA GGC ATC TCC TAT GGC AGG AAG AAG CGG-3’ and ED14 5’-TCT TGC
CTG GAG CTG TTT GAT GCC CCA GAC-3’) and then the second round primers envB/
ED12 (envB 5’-AGA AAG AGC AGA AGA CAG TGG CAA TGA-3’ and ED12 5’-AGT
GCT TCC TGC TGC TCC CAA GAA CCC AAG-3’). Note that for PCR from PBMC samples,
no RT reaction was performed and only the PCR primers were used for amplification. The RT
reaction condition was 37°C for 60 min with a second step of 90°C for 5 min (First Strand
cDNA Synthesis kit, Amersham Biosciences, Piscataway, NJ). The PCR thermal cycling
conditions for both rounds of PCR started with an initial denaturing step at 94°C for 2 min,
then 30 cycles of 94°C for 15 sec, 55°C for 30 sec, 72°C for 3 min, with a final 72°C for 12
min (60 cycles total). Taq DNA Polymerase and buffer components were supplied by Sigma-
Aldrich (St. Louis, MO).
Cloning and sequencing of PCR products—All resulting PCR reaction products were
cloned into a bacterial plasmid (pCR 2.1-TOPO; Invitrogen, Carlsbad, CA) using the
manufacturer’s recommended protocol and sequenced using BigDye 3.1 reaction mix and an
ABI-3100 automated DNA sequencer (Applied Biosystems, Foster City, CA). Eight
sequencing primers were used to provide coverage of both strands of the gp120 sequence:
M13F 5’-GTAAAACGACGGCCAG-3’; BSEQF1 5’-ACCACTCTA-
TTTTGTGCATCA-3’; BSEQF2 5’-AAACTGCTCTTTCAAT-GTCACCACA-3’; ES7 5’-
CTGTTAAATGGCAGTCTAGC-3’; BSEQF4 5’-TCAAATATTACAGGGCTGCTA-
TTAACAAG- 3’; BSEQR2 5’-GTTGTATTACAGTAGAAAAATTCCCCTC- 3’; BSEQR3
5’-CTGCCATTTAAC-AGCAGTTGAGTTG-3’; and M13R 5’-
CAGGAAACAGCTATGAC-3’.
Phylogenetic analyses
A total of 89 sequences were collected from nine different time points from a single individual
from the VAX004 Phase 3 AIDSVAX vaccine trial (Table 1). These sequences were translated
into amino acids and then aligned using Clustal X.22 In addition to inferring positional
homology in this amino acid data set, the alignment was loaded into the alignment editor Se-
Al23 to check for possible errors and stop codons. Samples that contained frame shifts or stop
codons were excluded from subsequent analyses leaving a final aligned data set of 86 gp120
sequences.
Fifty-six models of evolution were compared within a maximum likelihood (ML) framework
using the Akaike Information Criterion (AIC) as implemented in ModelTest3.724 and outlined
in Posada and Buckley.25 The chosen model of evolution was then implemented into
PAUP*v4b1026 to estimate an ML tree27 for the full data set. ML searches were run using
100 random addition replicates and TBR branch swapping. Confidence in the resulting
relationships was assessed using the nonparametric bootstrap procedure28 with 500 replicates,
using heuristic searches with one random sequence addition and TBR branch swapping per
replicate. Independent models of evolution for first, second, and third positions in the codon
triplets were also estimated using ModelTest. These three models were then implemented in
JOBES et al. Page 3
AIDS Res Hum Retroviruses. Author manuscript; available in PMC 2007 September 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
MrBayes3.1.129 to perform a mix-model Bayesian analysis coupled with Markov chain Monte
Carlo (BAMCMC) of the full data set. Two independent BAMCMC analyses were run with
each consisting of eight Markov chains. Each chain was started from a random tree and run
for 1 × 107 cycles, sampling every 1000th generation. Model parameters were treated as
unknown variables with uniform default priors and were estimated as part of the analysis.
Convergence and mixing were monitored using the program Tracer v1.2.30 All sample points
prior to reaching stationarity were discarded as burn-in. The posterior probabilities (pP) for
individual clades obtained from separate analyses were compared using the sumt command in
MrBayes and combined and summarized on a 50% majority-rule-consensus tree.31 The ML
and BAMCMC resulting trees were midpoint-rooted for easier visualization. Sequences were
also aligned with other sequences from the laboratory (including the vaccine antigens), known
laboratory strains, and other common subtypes to guard against contamination, mislabeling,
and misidentification.32 The data set showed no signs of contamination or mislabeling and all
gp120 sequences were classified as HIV-1 subtype B (data not shown).
Population dynamics
Identifying recombinants, especially among viruses of the same subtype, can be problematic.
Based on both simulation studies33–35 and empirical results from HIV-1,36 methods to detect
recombinants perform differentially well based on the overall genetic diversity in the data set
with the typically used (in HIV-1 studies) phylogenetic methods tending to perform more
poorly than substitution pattern approaches. Therefore, we chose to test for recombination
using a variety of methods shown to be useful in detecting recombinants in these earlier studies,
including MaxChiGlobal,34 PhylPro,37 Geneconv,38 and several recombination detection
tools implemented in the software TOPALi39 and RDP2.40
We estimated genetic diversity (θW) and the population recombination rate (ρ) using the
standard likelihood coalescent approach implemented in the LDhat2.0 package.41 Within this
framework ρ can be expressed as 2Ner, where Ne is again the effective population size and r
is the recombination rate per gene per generation. This method relaxes the infinite-sites
assumption (typically violated by many empirical data sets 36) and accommodates different
models of molecular evolution. LDhat2.0 also includes a powerful likelihood permutation test
(LPT) to test the hypothesis of no recombination (ρ = 0). LDhat implements a corrected version
(i.e., based on a finite-sites model) of the algorithm of Watterson42 for estimating θW. This
estimator relies on the number of segregating sites in the sequences and it has been shown that
although less efficient than coalescent ML, θW is still remarkably good.43,44
Adaptive selection
Adaptive selection at the molecular level is usually assessed by comparing the fixation rates
of nonsynonymous (amino acid-altering) and synonymous (silent) substitutions within an ML
phylogenetic framework45 estimating the nonsynonymous/synonymous substitution rate ratio
or ω= dN/dS. ω measures the selective pressure at the protein level, with ω = 1 suggesting
neutral evolution, ω < 1 negative selection, and ω > 1 positive selection. We inferred the extent
of selection by estimating ω and the proportion of sites (p) with ω > 1 under the models M0
(one ratio), M1 (neutral), M2 (selection), M3 (discrete), M7 (beta), and M8 (beta and ω) of
Goldman and Yang46 and Yang et al.45 Likelihood scores for the following nested models
were compared using likelihood ratio tests (LRT): M0–M3, M1–M2, and M7–M8. We also
applied the empirical Bayesian approaches implemented by Nielsen and Yang47 and Yang et
al.48 to identify the potential sites under diversifying selection as indicated by a posterior
probability (pP) > 0.95. All these analyses were carried out in PAML3.1449 and were
performed under initial ω values > and <1, as recommended by the author. Here we report the
ML estimates. ML trees were estimated for each clade under the bestfit substitution models.
JOBES et al. Page 4
AIDS Res Hum Retroviruses. Author manuscript; available in PMC 2007 September 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
RESULTS
Phylogenetic analyses
The Akaike Information Criterion (AIC), as implemented in ModelTest3.724 and outlined in
Posada and Buckley,25 was used to select the most appropriate model of evolution from 56
different models, compared within an ML framework. The chosen model of evolution was then
implemented into PAUP*v4b1026 to estimate an ML tree27 for the full data set. Under the
AIC criterion the optimized model of evolution chosen for the entire data set of 86 sequences
resulted in the TVM+I+Γ model, a model often found for HIV-1 sequences.50 The ML
parameters associated with this model were as follows: base frequencies A = 0.3622, C =
0.1811, G = 0.2233, T = 0.2334, rate parameters of R1 = 2.0370, R2 = 7.0780, R3 = 0.6577,
R4 = 0.4955, R5 = 7.0780, and R6 = 1.0, an alpha value for the gamma shape distribution of a
= 0.9108, and a proportion of invariable sites of 0.4104. Using this model, we estimated an
ML tree of evolutionary relationships (Fig. 1). Model testing under the AIC criterion for first,
second, and third positions of the alignment resulted in the following models: GTR+I+Γ, GTR
+Γ, and TVM+I+Γ, respectively. These three models were incorporated under the mixed-model
Bayesian estimation. The resulting BMCMC tree was almost identical to that depicted in Fig.
1, but with greater clade support. The resulting phylogeny showed two distinct monophyletic
groups of sequences, labeled as clades A and B, and a small group of three sequences clearly
distinct connecting them (recombinant A&B). This topology is suggestive of recombination
between clades A and B. The long branches separating these clades were supported by high
bootstrap values (100%) and high posterior probabilities (1.0). The earliest time point
(16OCT00 or 101600 as labeled on the phylogeny) was found in all lineages. Lineage B
includes only members of this time point (T1) and the next time point in sampling (20NOV00
or 112000; T2). All subsequent time points are found exclusively in lineage A. Within this
clade, longitudinal separation of time points T1–5, T6, and T7–9 can be observed. The recA&B
group included the following three sequences: 101600C5, 101600C14, and 101600C12, all
from T1.
Genetic divergence (GD) between and within strains based on corrected distances under the
TVM+I+ Γ model is shown in Table 2. Clade A (0.000–0.049) showed greater GD between
clones than clade B (0.001–0.013), but at least two times smaller than the GD observed between
strains (0.097–0.131). The recA&B showed intermediate values of GD within clones
(0.0090.022) and, as reflected in our trees, lower GD with clade B (0.032–0.059) than with
clade A (0.051–0.095).
Detection of recombinants
As suggested in the initial phylogenetic analyses (Fig. 1), the presence of recombination in the
full data set was confirmed by the MaxChiGlobal test (p < 0.001). The phylogenetic profile
analysis of the whole alignment (Fig. 2) and the distance plots obtained in RDP2 (Fig. 3)
indicate that two or three recombination events seemed to have occurred at the beginning of
the infection, giving rise to the recA&B group, with breakpoints around nucleotide positions
830, 966, and 1224, respectively. We used breakpoints 830 and 1224 to divide the whole
alignment into three subregions and ML trees were constructed for each of them separately
under the bestfit models (Fig. 4). Clear clustering by phylogenetic analysis of subregions of
gp120 sequences highlights the regional contribution of the two parent populations to the
construction of the new recombinant gp120 molecules (Fig. 4).
Evolutionary dynamics of intrasubtype B strains
We characterized the population dynamics of this volunteer’s infecting virus with estimates of
genetic diversity generated by mutation (θW) and recombination (ρ) for each strain and time
point(s) (Table 3). θW and ρ were higher for clade A (θW = 0.039, ρ = 81%) compared to rates
JOBES et al. Page 5
AIDS Res Hum Retroviruses. Author manuscript; available in PMC 2007 September 19.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
estimated for clade B (θW = 0.011, ρ = 2%). Sample size differences between strains are a
concern when interpreting these estimates. These sample differences by themselves illustrate
different evolutionary dynamics: clade A was present in all time points sampled (20-month
period), but clade B did not appear in plasma or blood after the second time point (2 months).
Nevertheless, genetic differences between clades A and B were clear since the first time point,
as indicated by the θW and ρ estimates: θW and ρ were considerably higher for clade A at T1
and T2 or T1–2 (0.021–0.028 and 20–67, respectively) than they were for clade B (0.004–
0.011 and 0–2, respectively) at the same time points (Table 3). Within clade A, θW diminishes
after T4 probably as a result of a dramatic reduction in viral load (i.e., effective population
size) due to the beginning of ART therapy application. We tested for positive selection by
obtaining likelihood values and parameter estimates for different codon-substitution models
of selection (Table 4). Model comparisons M0–M3, M1–M2, and M7–M8 for lineage B were
not significant as indicated by the LRTs, hence no evidence of positive selection was observed.
Consistent and significant strong levels of selection (ω = 4), however, for more than 5% of the
sites were detected under site-specific models for lineage A. Under these models the Bayesian
approaches were able to detect 8–16 sites under positive selection (pP > 0.95). Simulations by
Anisimova et al.51 indicate that high levels of recombination (C ≈ 0.01), as those reported here
for clade A, seem to affect dramatically the accuracy of the LRT test of models M0–M3 and
M1–M2 but much less the LRT of models M7–M8, and often mistakes recombination as
evidence of positive selection. Identification of sites under positive selection, however, using
the Bayesian approach appears to be less affected.51 However, when data were simulated at
very high levels (ω = 6) of positive selection (similar to those observed in our study) and the
population was expanding, the LRT and Bayesian test become more accurate and powerful
(concrete values are not reported). Therefore, although we think that recombination is probably
inflating our PAML estimates of positive selection, the observed values are so high that it is
clear that natural selection is a significant driving force in the evolution of these sequences as
well. Previous work has also demonstrated convincing evidence for both adaptive selection
and recombination.45,52,53
DISCUSSION
Reports in the literature of dual infection are rare; for instance, superinfection has been
documented in only 16 cases so far and most of those involved infection with different HIV
subtypes.2 Due to the difficulty of detection, intrasubtype dual infections would be expected
to be even more rarely reported. In the absence of substantive clinical indications of a dual
infection (e.g., increases in viral load or accelerated disease progression while on drug therapy),
the ability to detect multiple infection events is generally limited to molecular or serological
analyses. However, even using molecular techniques, the detection of dual infection and
recombination can be problematic for several reasons, especially if infection occurs with HIV
isolates of the same subtype. For example, inadequate or improper use of phylogenetic and
recombination detection methods, insufficient longitudinal sampling, and the use of partial
gene sequences instead of complete genes or genomes make it likely that estimates of dual
infection and recombination are underestimated in many at-risk populations.
In this study we reported on an individual from a Phase 3 HIV vaccine efficacy trial who was
infected with multiple HIV strains and a recombinant population, despite receiving repeated
vaccinations with a recombinant gp120-based vaccine. This study clearly demonstrates the
importance of sampling close to the infection event in order to detect dual infection. Indeed,
if the initial sampling took place after the second time point, clade B and the recA&B clade
would never have been sampled.
In the current study, we also thoroughly document recombination using multiple phylogenetic
and pattern matching methods. We expect that the recA&B clade is indeed a true recombinant
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group (i.e., and not generated by PCR) for the following reasons: (1) the recombinant
breakpoints, while closely associated by region, are distinct, suggesting that more than one
recombination event generated these new mutants and (2) despite at least three breakpoints at
the approximate positions 830, 966, and 1224, all three gp120 sequences recombined to form
an uninterrupted open reading frame. For this study, in fact, we only used sequences with full
open reading frames (i.e., presumably functional molecules), to reduce the risk of analyzing
nonfunctional sequences.
While phylogenetic methods are not always reliable predictors of recombination, in this case,
both phylogenetic and pattern matching methods substantiated the recombinants and clearly
differentiated the three populations (Figs. 1 and 4). While it is widely known that recombination
occurs frequently in vivo,17,18,54 it is unclear how common recombination is between viruses
from different infection events and in various geographic regions. For example, in Africa
circulating recombinant forms are widespread and can make up a large percentage of the virus
population in many countries,55–57 whereas recombination in North American viruses is
seldom observed. Indeed this is partly a consequence of the fact that recombination between
subtypes is much more easily detected than within subtypes and that there are far fewer subtypes
circulating in North America (predominantly subtype B). This study thus complements prior
studies reporting evidence of recombination between different strains of a single HIV-1
subtype,11,12 which taken together indicate that recombination of viral genomes within the
different strains present in an infected individual may constitute a significant factor in the
generation of HIV-1 diversity.11
Differences in sample size per time point (Table 1) suggest important differences in population
dynamics between invasive strains since we see no representation of lineage B or the
recombinant recA&B after time point two (before treatment with ART therapy). Population
dynamics can be efficiently studied using explicit statistical models of evolution, such as the
coalescent58 and the ML27 approaches that describe their effect on gene sequences. Here we
used different implementations of these approaches to compare key population parameters such
asθ, ρ, andω. between two HIV-1 strains. Observed significant differences in these parameters
confirm sampling observations. Clade B is much more homogeneous than clade A, as indicated
by their lower values of genetic diversity (θW) and recombination (ρ) (Table 3) and genetic
divergence (Table 2). We found no evidence of adaptive selection in clade B (Table 4); hence,
based on the gp120 gene region analyzed, it can be postulated that clade B viruses were not
able to escape the immune system and ultimately failed to establish. Nevertheless, other factors
such as different growth kinetics or stochastic loss due to severe viral drop (only for the later
time points) cannot be ruled out to explain the failure of this strain. After the second month of
infection, clade A began to dominate the viral population and eventually took over completely
(Table 1). High levels of selection pressure on this clade were observed (Table 4), as expected
for populations subjected to significant immunological pressure. Finally, the phylogeny itself
(Fig. 1) also reflects this difference in growth rate among the strains and also the relative
increase in fitness due to adaptation experienced by clade A as evidenced by the different
clustering of the samples: early samples (T1–5) are depicted at the bottom of clade A and late
samples (T7–9) at shallower nodes, with sample T6 in an intermediate position.
In summary, this study reports a case of coinfection and recombination from an HIV vaccine
efficacy trial. As part of this presumably single infection event, this trial participant harbors
two major virus populations and a small recombinant group, all of subtype B. Under the same
host and treatment conditions it has been demonstrated that these three virus populations
responded with different evolutionary dynamics over a period of about 2 years probably
because of their different genetic backgrounds. This study underscores the need for a much
larger survey to document the actual prevalence of multiple infection and recombination events
in both vaccine and placebo groups from trial populations to better understand the relative
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population dynamics of HIV evolution in high-risk populations and in response to vaccine
treatment.
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FIG 1.
Maximum likelihood estimate of phylogenetic relationships. A mix model Bayesian analysis
generated almost the same relationships. Clades supported by bootstrap values ≥ 70% and/or
posterior probabilities ≥ 0.95 are indicated with an asterisk (*) on the branches. Branch lengths
are shown proportional to the amount of evolutionary change. The sequence labels are
described in Table 1 and sequence labels are coded by collection date.
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FIG 2.
Phylogenetic profile analysis of the whole alignment.37 Negative correlation values (x-axis)
indicate recombination breakpoints. Sequences 060302P83 and 060302P85 were excluded
from the analysis because they contained many gaps. Low correlation values at the beginning
and at the end of the alignment are noise.
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FIG 3.
Distance plots obtained in RDP2 for the three putative recombinant sequences against two
representatives of the two subtype B lineages.
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FIG 4.
Maximum likelihood phylogenetic trees for three different subregions of the alignment.
Recombinant sequences are highlighted.
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TABLE 2
Genetic Divergence Range within and between Clades A, B, and the Recombinant A & B (RecA&B) Based on
Corrected Distances Estimated under the TVM+I+Γ Model of Evolution
Clade A Clade B RecA&B
Clade A 0.000–0.049 0.097–0.131 0.051–0.095
Clade B 0.097–0.131 0.001–0.013 0.032–0.059
RecA&B 0.051–0.095 0.032–0.059 0.009–0.022
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TABLE 3
Estimates of Genetic Diversity (θW) and Population Recombination Rate (ρ)a
θW ρ
Strain AT1–9 0.039 81*** Strain AT1 0.021 20*** Strain AT2 0.025 58*** Strain AT3 0.021 75*** Strain AT4 0.019 3*** Strain AT5 0.009 0*** Strain AT6 0.008 0*** Strain AT7 0.003 0*** Strain AT8 0.007 0*** Strain AT9 0.009 0*** Strain AT1–2 0.028 67***
Strain BT1–2 0.011 2*** Strain BT1 0.009 1*** Strain BT2 0.004 0***
a
The probability of ρ = θ (indicated by asterisks) from the LPT test is also indicated. Sequences 060302P83 and 060302P85 were excluded from the
analysis because they contained many gaps.
**
p < 0.01;
***
p < 0.001.
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